Coexisting Medical Conditions, Hodgkin Lymphoma
Conditions
Keywords
Nivolumab, Lymphoma, Anti-PD1
Brief summary
This study is a multicentric phase II open-label trial consisting of 6 cycles Nivolumab (2 weeks interval) followed by a PET-CT scan. The treatment will be allocated according to PET and CT scan responses. : * In case of CMR according to Lugano Classification (Cheson et al.2014, PET-CT based response), patients will receive 18 additional cycles of Nivolumab, according to CT-based response at Cycle 12. * In case of Partial Metabolic Response (PMR) or No Metabolic Response(NMR), according to Lugano Classification (Cheson et al.2014, PET-CT based response) patients will receive 12 to 18 cycles of Nivolumab combined with Vinblastin according to CT-based response at Cycle 12. * In case of progressive disease, according to Lugano Classification (Cheson et al.2014, PET-CT scan based response) patients will be considered in treatment failure.
Interventions
DRUGNivolumab
240 mg
DRUGVinblastin
6mg/m²
Sponsors
The Lymphoma Academic Research Organisation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
61 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* first diagnosis of classical Hodgkin lymphoma according to World Health Organization (WHO) criteria excluding nodular lymphocyte predominant subtype * Age 61 years or older * Unfit for poly chemotherapy because of co-morbidities evaluated by a Cumulative Illness Rating Scale (CIRS) score ≥6) * No previous treatment for Hodgkin lymphoma * Ann Arbor stages: I-IV * Baseline 18-fluoro-2-deoxy-D-glucose (18F-FDG) PET-CT (PET0) performed before any treatment with at least one hypermetabolic lesion * Eastern Cooperative Oncology Group (ECOG) performance status 0-3 * minimum life expectancy of 3 months * covered by a social security system * Men who are sexually active with women with childbearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug and for at least 7 months after the last drug administration.
Exclusion criteria
* Contra-indication to Nivolumab and /or Vinblastin * Subjects with active interstitial pneumonitis * Subjects with active infectious disease * Subjects with active, known or suspected autoimmune disease. Are permitted to enroll: subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger. * Any serious active disease, severe cardio-pulmonary, or metabolic disease interfering with normal application of protocol treatment (according to the investigator's decision) * Any of the following abnormal laboratory values (unless due to underlying HL) : 1. Calculated creatinine clearance \< 30 mL/min (MDRD formula) 2. aspartate transaminase (AST) or alanine transaminase (ALT) \> 2.5 times the upper limit of normal (ULN) 3. Serum total bilirubin \> 30µmol/L 4. Neutrophils\<1 G/L or Platelets\<50 G/L, (unless related to bone infiltration by lymphoma) * Any history of cancer evolution requiring therapy during the last 3 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma. Patients previously diagnosed with prostate cancer are eligible if : 1. Their disease was T1-T2a, N0, M0, with a Gleason score ≤ 7, and a prostate specific antigen (PSA) ≤ 10 ng/mL prior to initial therapy, 2. They had definitive curative therapy (ie, prostatectomy or radiotherapy) ≥ 2 years before Day 1 of Cycle 1, 3. At a minimum 2 years following therapy they had no clinical evidence of prostate cancer, and their PSA was undetectable if they underwent prostatectomy or \<1 ng/mL if they did not undergo prostatectomy. * Uncontrolled diabetes mellitus leading to impossibility to perform PET scan * Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study * Adult person under legal protection * Adult person unable to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness * Subjects with know Human Immunodeficiency Virus (HIV) positivity * Subjects with known active hepatitis B (HB) infection (positive Ag HB s or positive DNA polymerase chain reaction (PCR) or positive antibody anti-HB c with lack of antibody against HBs) or active hepatitis C infection (patients with positive HCV serology are eligible only if PCR is negative for known hepatitis C virus (HCV RNA) * Subjects with a condition requiring systemic treatment with either corticosteroids (\> 10mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration except for adrenal replacement steroid doses \> 10 mg daily prednisone equivalent in the absence of active autoimmune disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete Metabolic Response (CMR) rate (Deauville scale 1-3) at the end of treatment | 12 months | by the Lugano classification 2014 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Serious Adverse Event | 12 months | — |
| Progression-free survival (PFS) | 5 years | — |
| Quantity of drug taken | 12 months | — |
| Overall survival (OS) | 5 years | — |
| Complete Metabolic Response (CMR) rate | 3 months | by the Lugano classification 2014 at the end of induction treatment |
| Event-free survival (EFS) | 5 years | — |
Countries
Belgium, France
Outcome results
None listed